Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe Sells 2,500 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 2,500 shares of the company’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $47.10, for a total transaction of $117,750.00. Following the completion of the sale, the senior vice president now owns 2,426 shares of the company’s stock, valued at approximately $114,264.60. This represents a 50.75 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock traded down $1.76 during midday trading on Friday, reaching $44.50. The company’s stock had a trading volume of 605,104 shares, compared to its average volume of 559,796. The company has a current ratio of 3.34, a quick ratio of 3.09 and a debt-to-equity ratio of 1.33. The stock has a market cap of $2.14 billion, a PE ratio of -22.09 and a beta of 1.16. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $48.89. The business has a 50-day moving average price of $40.06 and a 200-day moving average price of $35.86.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. During the same quarter in the previous year, the firm posted ($0.57) earnings per share. The company’s revenue was up 89.4% on a year-over-year basis. On average, sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.81 EPS for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. Janus Henderson Group PLC increased its stake in shares of Mirum Pharmaceuticals by 34.2% in the first quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company’s stock valued at $69,470,000 after buying an additional 704,659 shares during the period. Candriam S.C.A. bought a new stake in Mirum Pharmaceuticals in the second quarter valued at approximately $17,384,000. Loomis Sayles & Co. L P acquired a new stake in Mirum Pharmaceuticals during the 3rd quarter valued at approximately $19,473,000. Clearbridge Investments LLC raised its holdings in Mirum Pharmaceuticals by 165.5% during the 2nd quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock worth $23,931,000 after purchasing an additional 436,349 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Mirum Pharmaceuticals by 37.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock worth $40,131,000 after purchasing an additional 432,824 shares during the last quarter.

Wall Street Analysts Forecast Growth

MIRM has been the topic of a number of research reports. Citigroup lifted their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald raised their target price on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday. Robert W. Baird upped their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Evercore ISI raised their price objective on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Ten investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $57.73.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.